Fibrocell Science Company Profile (NASDAQ:FCSC)

About Fibrocell Science

Fibrocell Science, Inc. is an autologous cell and gene therapy company. The Company is focused on discovering and developing localized therapies for diseases affecting the skin, connective tissue and joints. Its product candidate, azficel-T, is in development to treat patients suffering from vocal cord scarring that is either idiopathic or age-related. It is investigating the indication in a Phase II clinical trial. Its gene-therapy product candidate, FCX-007, is in pre-clinical development for the treatment of recessive dystrophic epidermolysis bullosa. Its gene-therapy product candidate, FCX-013, is in pre-clinical development for the treatment of linear scleroderma. Its product, LAVIV (azficel-T), is indicated for the improvement of the appearance of moderate to severe nasolabial fold wrinkles in adults. A third gene-therapy program is focused on the treatment of arthritis. Its product, LAVIV (azficel-T), is focused on improving the appearance of nasolabial fold wrinkles in adults.

Industry, Sector and Symbol:

Sector: Medical
Industry: Drugs - Generic
Sub-Industry: N/A
Exchange: NASDAQ
Symbol: FCSC
CUSIP:

Key Metrics:

Previous Close: $0.72
50 Day Moving Average: $0.90
200 Day Moving Average: $1.63
52-Week Range: $0.71 - $6.18
Trailing P/E Ratio: N/A
Foreward P/E Ratio: -1.57
P/E Growth: 0.00
Market Cap: $31.61M
Outstanding Shares: 43,898,000
Beta: 0.45

Profitability:

Net Margins: -10,860.23%
Return on Equity: -124.33%
Return on Assets: -72.26%

Debt:

Current Ratio: 2.83%
Quick Ratio: 2.80%

Additional Links:

Companies Related to Fibrocell Science:

Consensus Ratings for Fibrocell Science (NASDAQ:FCSC) (?)

Ratings Breakdown:	1 Hold Rating, 3 Buy Ratings
Consensus Rating:	Buy (Score: 2.75)
Consensus Price Target:	$5.63 (681.25% upside)

Analysts' Ratings History for Fibrocell Science (NASDAQ:FCSC)

Show:

Date	Firm	Action	Rating	Price Target
8/7/2016	Canaccord Genuity	Reiterated Rating	Buy	$1.50
7/6/2016	Griffin Securities	Reiterated Rating	Buy	$12.00
6/8/2016	Roth Capital	Reiterated Rating	Buy	$5.00
6/8/2016	Wedbush	Reiterated Rating	Neutral	$1.50 -> $4.00

(Data available from 9/29/2014 forward)

Earnings History for Fibrocell Science (NASDAQ:FCSC)

Date	Quarter	Consensus Estimate	Actual EPS	Release Link	Conference Call
11/3/2016
8/4/2016	Q216	($0.15)	($0.18)	View	N/A
5/5/2016	Q1	($0.15)	($0.03)	View	N/A
3/10/2016	Q415	($0.17)	($0.40)	View	Listen
11/5/2015	Q315	($0.16)	($0.07)	View	N/A
8/6/2015	Q215	($0.16)	($0.17)	View	N/A
5/8/2015		($0.16)	($0.17)	View	N/A
3/13/2015		($0.16)	($0.08)	View	N/A
11/7/2014	Q3 14	($0.14)	($0.17)	View	N/A
8/11/2014		($0.18)	($0.08)	View	N/A
5/19/2014	Q114	($0.15)	($0.35)	View	N/A
3/17/2014	Q414	($0.26)	($0.14)	View	N/A

(Data available from 1/1/2011 forward)

Earnings Estimates for Fibrocell Science (NASDAQ:FCSC)

Current Year EPS Consensus Estimate: $-0.49 EPS
Next Year EPS Consensus Estimate: $-0.46 EPS

Quarter	Number of Estimates	Low Estimate	High Estimate	Average Estimate
Q1 2016	3	($0.18)	($0.14)	($0.16)
Q2 2016	3	($0.22)	($0.09)	($0.15)
Q3 2016	3	($0.19)	($0.06)	($0.12)
Q4 2016	3	($0.22)	($0.07)	($0.13)
Q1 2017	4	($0.20)	($0.07)	($0.14)
Q2 2017	4	($0.20)	($0.07)	($0.14)
Q3 2017	4	($0.21)	($0.05)	($0.13)
Q4 2017	3	($0.17)	($0.05)	($0.11)

(Data provided by Zacks Investment Research)

Dividend History for Fibrocell Science (NASDAQ:FCSC)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for Fibrocell Science (NASDAQ:FCSC)

Insider Ownership Percentage: 3.70%
Institutional Ownership Percentage: 61.89%

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction
11/13/2015	David Pernock	CEO	Buy	3,000	$5.00	$15,000.00
8/11/2015	David Pernock	CEO	Buy	3,500	$6.54	$22,890.00
7/27/2015	Randal J Kirk	Major Shareholder	Buy	975,987	$5.80	$5,660,724.60
5/13/2015	David Pernock	CEO	Buy	16,600	$4.30	$71,380.00
12/12/2014	David Pernock	CEO	Buy	5,000	$2.52	$12,600.00
11/20/2014	David Pernock	CEO	Buy	5,000	$2.54	$12,700.00
11/20/2014	John Michael Maslowski	VP	Buy	1,000	$2.54	$2,540.00
6/5/2014	Christine St.Clare	Director	Buy	10,000	$3.00	$30,000.00
6/5/2014	David Pernock	CEO	Buy	12,500	$2.95	$36,875.00
6/4/2014	Kelvin Moore	Director	Buy	4,557	$2.99	$13,625.43
6/4/2014	Randal J Kirk	Major Shareholder	Buy	400,000	$2.90	$1,160,000.00
1/24/2014	Randal J Kirk	Major Shareholder	Buy	1,024,590	$4.88	$4,999,999.20
11/21/2013	David Pernock	CEO	Buy	10,000	$3.69	$36,900.00
11/20/2013	Gregory L Weaver	CFO	Buy	10,000	$3.51	$35,100.00
10/1/2013	Randal J Kirk	Major Shareholder	Buy	3,658,536	$4.10	$14,999,997.60
7/26/2013	Randal J Kirk	Major Shareholder	Buy	1,243,781	$6.03	$7,499,999.43

(Data available from 1/1/2013 forward)

Latest Headlines for Fibrocell Science (NASDAQ:FCSC)

Date	Headline
	Fibrocell to Present at 2016 Cell & Gene Meeting on the Mesa - GlobeNewswire (press release) (NASDAQ:FCSC) globenewswire.com - September 29 at 4:55 PM
	Fibrocell Science Inc (FCSC) Updated Broker Price Targets - The De Soto Edge (NASDAQ:FCSC) desotoedge.com - September 29 at 4:55 PM
	Fibrocell to Present at 2016 Cell & Gene Meeting on the Mesa (NASDAQ:FCSC) finance.yahoo.com - September 29 at 10:01 AM
	Interested Penny Stock Investors Keen on Shares of Fibrocell Science, Inc. (NASDAQ:FCSC) - Duncan Research (NASDAQ:FCSC) www.duncanindependent.com - September 28 at 4:51 PM
	Current Price Targets For Fibrocell Science Inc (FCSC) - NewsDen (NASDAQ:FCSC) newsden.net - September 28 at 4:51 PM
	Can Shares Of Fibrocell Science Inc (NASDAQ:FCSC) Hit $6? - Investor Newswire (NASDAQ:FCSC) www.investornewswire.com - September 28 at 4:51 PM
	Penny Stock Investors are Growing Curious About Fibrocell Science, Inc. (NASDAQ:FCSC) - Duncan Research (NASDAQ:FCSC) www.duncanindependent.com - September 28 at 9:53 AM
	ETF’s with exposure to Fibrocell Science, Inc. : September 27, 2016 (NASDAQ:FCSC) www.capitalcube.com - September 27 at 4:59 PM
	Fibrocell Science Inc (FCSC) Receives Neutral Rating from Wedbush - DailyQuint (NASDAQ:FCSC) dailyquint.com - September 23 at 9:58 AM
	Under the Microscope, Zeroing in at Fibrocell Science, Inc. (NASDAQ:FCSC) - Duncan Research (NASDAQ:FCSC) www.duncanindependent.com - September 23 at 9:58 AM
	Penny Stock Investors Take an Interest in Fibrocell Science, Inc. (NASDAQ:FCSC) - Duncan Research (NASDAQ:FCSC) www.duncanindependent.com - September 21 at 9:13 AM
	Fibrocell Science Incorporated (NASDAQ:FCSC) Sellers Covered 5.05% of Their Shorts - Post News (NASDAQ:FCSC) www.kentuckypostnews.com - September 19 at 3:54 PM
	Fibrocell Science (FCSC) Completes Enrollment in NC1+ Cohort of Phase I/II Clinical Trial of FCX-007 to Treat RDEB - StreetInsider.com (NASDAQ:FCSC) www.streetinsider.com - September 19 at 3:54 PM
	Fibrocell Completes Enrollment in NC1+ Cohort of Phase I/II Clinical Trial of FCX-007 for Treatment of Recessive Dystrophic Epidermolysis Bullosa (NASDAQ:FCSC) www.publicnow.com - September 19 at 9:39 AM
	Can Shares Of Fibrocell Science Inc (NASDAQ:FCSC) Hit $6 - Investor Newswire (NASDAQ:FCSC) www.investornewswire.com - September 16 at 8:45 AM
	ETF’s with exposure to Fibrocell Science, Inc. : September 15, 2016 (NASDAQ:FCSC) www.capitalcube.com - September 15 at 5:23 PM
	What's Propelling Fibrocell Science Inc to Reach 52-Week High? - Frisco Fastball (NASDAQ:FCSC) friscofastball.com - September 14 at 9:10 AM
	Fibrocell Announces Closing of $18 Million Private Placement - GlobeNewswire (press release) (NASDAQ:FCSC) globenewswire.com - September 10 at 4:40 PM
	Fibrocell finalizes $18M convertible debt offering - Seeking Alpha (NASDAQ:FCSC) seekingalpha.com - September 10 at 4:40 PM
	Gene therapy company raises $18M (NASDAQ:FCSC) www.bizjournals.com - September 9 at 4:51 PM
	Fibrocell Science Inc (NASDAQ:FCSC) Gets 0 Recommendations To Sell - Investor Newswire (NASDAQ:FCSC) www.investornewswire.com - August 25 at 9:58 AM
	ETF’s with exposure to Fibrocell Science, Inc. : August 23, 2016 (NASDAQ:FCSC) www.capitalcube.com - August 23 at 5:07 PM
	Shares Dipping Lower in Trade: Fibrocell Science, Inc. (NASDAQ:FCSC) - Post News (NASDAQ:FCSC) www.kentuckypostnews.com - August 22 at 5:02 PM
	Will Fibrocell Science Inc (NASDAQ:FCSC) Hit $12 Price Target? - Investor Newswire (NASDAQ:FCSC) www.investornewswire.com - August 18 at 5:37 AM
	FIBROCELL SCIENCE, INC. Financials (NASDAQ:FCSC) finance.yahoo.com - August 13 at 4:53 PM
	ETF’s with exposure to Fibrocell Science, Inc. : August 11, 2016 (NASDAQ:FCSC) www.capitalcube.com - August 11 at 5:09 PM
	Fibrocell Science Inc (NASDAQ:FCSC) & RR Donnelley & Sons Co (NASDAQ:RRD) Market Movers - Money News (press release) (NASDAQ:FCSC) www.newsismoney.com - August 10 at 11:11 PM
	Fibrocell Science (FCSC) Announces $25M Conv. Debt, Warrants Offering; Terminates Stock Offering (NASDAQ:FCSC) www.streetinsider.com - August 10 at 12:22 PM
	Fibrocell Science relaunches funding with convertible debt not equity (NASDAQ:FCSC) www.proactiveinvestors.com - August 10 at 12:22 PM
	Intrexon Announces Second Quarter and First Half 2016 Financial Results (NASDAQ:FCSC) www.publicnow.com - August 9 at 9:18 PM
	Fibrocell Science (FCSC) Announces $25M Conv. Debt, Warrants Offering; Terminates Stock Offering - StreetInsider.com (NASDAQ:FCSC) www.streetinsider.com - August 9 at 3:41 PM
	FIBROCELL SCIENCE, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct Financia (NASDAQ:FCSC) biz.yahoo.com - August 9 at 3:41 PM
	8:35 am Fibrocell Science terminates previously announced underwritten public offering, announces convertible debt and warrant financing for up to $25 mln (NASDAQ:FCSC) finance.yahoo.com - August 9 at 3:41 PM
	Fibrocell Announces Convertible Debt and Warrant Financing of Up to $25 Million (NASDAQ:FCSC) www.publicnow.com - August 9 at 3:41 PM
	Fibrocell Science, Inc. :FCSC-US: Earnings Analysis: Q2, 2016 By the Numbers : August 9, 2016 (NASDAQ:FCSC) www.capitalcube.com - August 9 at 3:41 PM
	Gene therapy company scraps public stock offering for private financing (NASDAQ:FCSC) www.bizjournals.com - August 9 at 3:41 PM
	Fibrocell Announces Proposed Public Offering of Common Stock and Warrants (NASDAQ:FCSC) finance.yahoo.com - August 8 at 5:06 PM
	Fibrocell Science reports 2Q loss (NASDAQ:FCSC) sg.finance.yahoo.com - August 4 at 5:18 PM
	HC Stocks in Front Line: Fibrocell Science Inc (NASDAQ:FCSC), Pfizer Inc. (NYSE:PFE) - share market updates (press release) (NASDAQ:FCSC) sharemarketupdates.com - August 2 at 9:50 AM
	Phase I Data Expected in the Second Half of 2017 (NASDAQ:FCSC) globenewswire.com - July 29 at 5:03 PM
	Can Shares Of Fibrocell Science Inc (NASDAQ:FCSC) Hit $12? - Investor Newswire (NASDAQ:FCSC) www.investornewswire.com - July 27 at 5:11 PM
	Fibrocell Announces First Subjects Enrolled in Phase I/II Clinical Trial of FCX-007 for Treatment of Recessive Dystrophic Epidermolysis Bullosa (NASDAQ:FCSC) www.publicnow.com - July 27 at 4:28 PM
	FIBROCELL SCIENCE, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits (NASDAQ:FCSC) biz.yahoo.com - July 27 at 4:08 PM
	Checking in on Stock Volatility for: Fibrocell Science, Inc. (NASDAQ:FCSC) - Engelwood Daily (NASDAQ:FCSC) www.engelwooddaily.com - July 22 at 6:19 AM
	Stock Soars, Rewards Investors Nicely Today: Fibrocell Science, Inc. (NASDAQ:FCSC) - Engelwood Daily (NASDAQ:FCSC) www.engelwooddaily.com - July 22 at 6:19 AM
	Is $12 Price Target Attainable For Fibrocell Science Inc (NASDAQ:FCSC)? - Investor Newswire (NASDAQ:FCSC) www.investornewswire.com - July 21 at 8:32 AM
	How Many Fibrocell Science Inc (NASDAQ:FCSC)'s Analysts Are Bearish? - Press Telegraph (NASDAQ:FCSC) presstelegraph.com - July 21 at 8:32 AM
	Fibrocell Science Inc Stock Technicals Hit Extreme Weakness - CML News (NASDAQ:FCSC) news.cmlviz.com - July 19 at 5:06 PM
	Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Rose 2.36%: Fibrocell Science, Inc. (NASDAQ:FCSC), Bank of America ... - KC Register (NASDAQ:FCSC) www.kcregister.com - July 19 at 5:06 PM
	Investor Watch: Volatility Recap on Shares of: Fibrocell Science, Inc. (NASDAQ:FCSC) - Engelwood Daily (NASDAQ:FCSC) www.engelwooddaily.com - July 19 at 5:06 PM